AstraZeneca Plc., the British-Swedish multinational biopharmaceutical company headquartered in Cambridge, UK, said in a statement on Saturday that the UK-based pharmaceutical company had signed off an accord with the European Governments according to which the British-Swedish drugmaker would be supplying 400 million doses of pandemic vaccines into the bloc, pointing towards a potential development in the global-scale squabble against the pandemic outbreak.
In point of fact, latest AstraZeneca deal with the European Governments was brought into light days after the British-Swedish biopharmaceutical company had proposed a merger with a US drugmaker, Gilead Sciences, whose pandemic drug Remdesivir has still been the last line of defence against the ongoing pandemic outbreak.
Aside from that, according to AstraZeneca’s Saturday’s statement, released late on the day, the British-Swedish biopharmaceutical, whose R&D (Research and Development) centres were mostly based on Cambridge, Maryland, Gaithersburg and Molndal in Sweden, had signed itself up for a contract of 400 million doses of pandemic vaccine developed by the University of Oxford, while the British-Swedish drugmaker had also added that it had been looking towards a potential expansion of its pandemic vaccine and the company would not seek profit during the periods of pandemic outbreak.
AstraZeneca set to become the first pharmaceutical to sign off a contract with Europe’s IVA (Inclusive Vaccine Alliance)
Meanwhile, adding that the Cambridge-based biopharmaceutical would begin deliveries by end-2020, AstraZeneca Chief Executive Pascal Soriot said to the reporters following the announcement of the deal, “This will ensure that hundreds of millions of people in Europe will have access to this vaccine, of course if it works and we will know that by the end of summer.
The alliance will work together with the European Commission and other countries in Europe to ensure everybody across Europe is supplied with the vaccine. ” Concomitantly, AstraZeneca becomes the first drugmaker to sign off a vaccine contract with Europe’s IVA (Inclusive Vaccine Alliance), an entity formed by France, Germany, Netherlands and Italy in order to secure a pandemic vaccine for all ‘bloc’ members as soon as possible. More than 200 pandemic vaccines were being in the process of development across the globe as of early-June.